Colon Cancer News and Research

Latest Colon Cancer News and Research

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

Bowel cancer affecting more and more Australians

Bowel cancer or colon cancer was till now considered a disease that affected elderly men. Recent trends however show that it is affecting more and more Australians in a younger age group.

6 Jun 2010

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris, researchers.

4 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

University of California scientists identify new kinase that regulates cell proliferation, migration

Scientists at the University of California, San Diego have identified a previously unknown kinase that regulates cell proliferation, shape and migration, and may play a major role in the progression or metastasis of cancer cells.

1 Jun 2010

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.

26 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

German states may face healthcare crisis: Study

Within the next ten years, there will be deficiencies in healthcare provision in parts of Mecklenburg-West Pomerania. This is the conclusion reached by Ulrike Siewert of Greifswald University and her coauthors in the current edition of Deutsches -rzteblatt International.

21 May 2010

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.

15 May 2010

NiTi Surgical Solutions completes over 4,000 successful ColonRing applications in 16 countries

NiTi™ Surgical Solutions, an innovative surgical device company, today provided an update of sales and clinical data highlights related to its lead product ColonRing™, the first major advance in reconnection technology for gastrointestinal surgery in more than 30 years.

14 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Colon Cancer News and Research

Latest Colon Cancer News and Research

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

Bowel cancer affecting more and more Australians

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

USC to present promising new findings in cancer research at 2010 ASCO

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

University of California scientists identify new kinase that regulates cell proliferation, migration

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

German states may face healthcare crisis: Study

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

NiTi Surgical Solutions completes over 4,000 successful ColonRing applications in 16 countries

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Colon Cancer News and Research

Latest Colon Cancer News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in